Clinical Trials

For a quick look at enrolling or soon to be enrolling investigational drug studies in Duchenne and their enrollment criteria, check out our Clinical Trial Cheat Sheet below.

Clinical Trial Finder

Use this Clinical Trial Finder below that can help provide you with more information regarding clinical trials in Duchenne that that you, your child, or your patient may be eligible for!

Watch Jett Foundation's Mini Satellite Presentation

Emerging Therapies for Duchenne Muscular Dystrophy

Presented by Jean Mah, M.D., Associate Professor of Pediatric Neurology Alberta Children’s Hospital at the 2016 Child Neurology Society Meeting to learn more about these potential therapies!

Latest Duchenne News

September 30, 2024

Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

Press release and Community Letter updates from Wave Life Sciences.

September 4, 2024

PepGen Mid Year 2024 Advocacy Newsletter

On September 4, 2024, PepGen shared their mid year advocacy newsletter with updates from Q2 and Q3. Please click here to view their newsletter.

September 3, 2024

Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts

Dyne Therapeutics announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251.

August 14, 2024

Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

On August 13, 2024, Solid Biosciences reported financial results for the second quarter ended June 30, 2024, and provided a business update. Please continue reading to view their press release. To...

August 9, 2024

Avidity Biosciences Shares Community Letter Announcing Positive Data From EXPLORE44™ for Duchenne Muscular Dystrophy

Avidity shares updates on EXPLORE44 trial in a community letter and press release.

August 6, 2024

REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202

Data updates for Phase I/II AFFINITY DUCHENNE® trial of RGX-202.

Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | [email protected]

Sitemap

Support Jett Foundation

Jett Foundation, Inc. is a 501(c)3 registered tax-exempt nonprofit organization. Our Federal Tax ID is 04-3563445.

Stay Connected With Us

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Programs

Events